Anaptysbio (ANAB) Other Accumulated Expenses (2016 - 2026)

Anaptysbio (ANAB) posted Other Accumulated Expenses of $17.8 million for Q1 2026, up 8.47% on a QoQ basis from $16.4 million in Q4 2025.

Anaptysbio (ANAB) Other Accumulated Expenses (2016 - 2026) Analysis & Trends

Anaptysbio's Other Accumulated Expenses history runs 9 years deep, the most recent figure standing at $17.8 million for Q1 2026.

Quarterly Other Accumulated Expenses changed N/A year-over-year to $17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.8 million (changed N/A YoY) and the FY2025 annual result came in at $16.4 million, down 45.71% from the prior year.
Other Accumulated Expenses was $17.8 million for Q1 2026 at Anaptysbio, up from $16.4 million in the prior quarter.
Across five years, Other Accumulated Expenses topped out at $30.2 million in Q4 2024 and bottomed at $16.4 million in Q4 2025.
A 3-year average of $21.5 million and a median of $17.8 million in 2026 frame the typical range for Other Accumulated Expenses.
Peak annual rise in Other Accumulated Expenses reached 45.71% in 2025, while the deepest fall reached 45.71% in 2025.
Anaptysbio's Other Accumulated Expenses stood at $30.2 million in 2024, then plunged by 45.71% to $16.4 million in 2025, then gained by 8.47% to $17.8 million in 2026.
Business Quant data shows ANAB's Other Accumulated Expenses at $17.8 million in Q1 2026, $16.4 million in Q4 2025, and $30.2 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Anaptysbio	1.58 Bn	1.29 Bn	-

Download Data